| Size | Price | |
|---|---|---|
| 5mg | ||
| Other Sizes |
| Targets |
The primary target is the glucocorticoid receptor (NR3C1); betamethasone binds GR with high affinity (Kd approximately 0.025 μM in [³H]dexamethasone binding assays) and activates GRE-mediated transcription, inducing anti-inflammatory proteins (e.g., annexin A1, IL-10) and suppressing pro-inflammatory cytokines and COX-2 expression.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Betamethasone-d5-1 retains the glucocorticoid receptor agonist activity of the unlabeled compound, with high GR binding affinity (Kd approximately 0.025 μM) and potent anti-inflammatory activity in cellular assays; 21-acetate esterification (as in betamethasone acetate) decreases GR binding affinity and increases lipophilicity, and the d5 standard is used to quantify betamethasone in receptor-binding and cellular assays. |
| ln Vivo |
In vivo, betamethasone is highly efficacious in inflammatory and autoimmune disease models (e.g., adjuvant arthritis, dermatitis) through GR-mediated suppression of cytokine production and inflammatory cell infiltration; the d5 internal standard supports PK studies quantifying betamethasone in plasma and tissue, and PK–PD relationships are established between GR occupancy and anti-inflammatory effect.
|
| Enzyme Assay |
Glucocorticoid receptor binding is measured with [³H]dexamethasone in rat thymus or liver cytosol or recombinant human GR; betamethasone-d5-1 or unlabeled betamethasone is incubated with cytosol and radioligand at 4°C for 16–24 h, and bound radioactivity is separated by dextran-coated charcoal and counted to derive Kd and relative binding affinity; the d5 standard is used for LC-MS/MS quantification.
|
| Cell Assay |
GR-mediated transactivation is measured in COS-7 or HEK293 cells co-transfected with human GR and a GRE-luciferase reporter; cells are treated with serial dilutions of betamethasone-d5-1 or unlabeled betamethasone, and luciferase activity is measured after 18–24 h; COX-2 and annexin A1 expression are quantified by Western blot, and the d5 tracer is used to correlate cellular uptake with GR activation.
|
| Animal Protocol |
In vivo anti-inflammatory efficacy is evaluated in rat carrageenan-induced paw edema or adjuvant arthritis models, with betamethasone-d5-1 or unlabeled betamethasone administered orally or intra-articularly at defined doses; paw volume and arthritis score are quantified, plasma and tissue concentrations of the d5 tracer are measured by LC-MS/MS, and GR occupancy is estimated by ex vivo [³H]dexamethasone binding.
|
| References |
|
| Molecular Formula |
C22H29FO5
|
|---|---|
| Molecular Weight |
392.46
|
| Exact Mass |
397.231
|
| CAS # |
2244574-92-1
|
| Related CAS # |
Betamethasone;378-44-9
|
| PubChem CID |
163321978
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.9
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
28
|
| Complexity |
805
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
[2H]C1C[C@H]2[C@@H]3C[C@@H]([C@@]([C@]3(C([C@]([C@@]2([C@@]4(C1=C(C(=O)C=C4)[2H])C)F)([2H])O)([2H])[2H])C)(C(=O)CO)O)C
|
| InChi Key |
UREBDLICKHMUKA-RXBGCOSMSA-N
|
| InChi Code |
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1/i4D,9D,10D2,17D/t4?,12-,15-,16-,17-,19-,20-,21-,22-
|
| Chemical Name |
(8S,9R,10S,11S,13S,14S,16S,17R)-4,6,11,12,12-pentadeuterio-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,14,15,16-hexahydrocyclopenta[a]phenanthren-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5480 mL | 12.7402 mL | 25.4803 mL | |
| 5 mM | 0.5096 mL | 2.5480 mL | 5.0961 mL | |
| 10 mM | 0.2548 mL | 1.2740 mL | 2.5480 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
